4 results match your criteria: "Osaka Gyoumeikan Hospital Osaka Japan.[Affiliation]"
Dissolution of Spontaneous Thrombi Responsible for Acute Coronary Syndrome for 1 Year.
Circ Rep
October 2021
Department of Cardiology, Osaka Gyoumeikan Hospital Osaka Japan.
Article Synopsis
- The CANONICAL study assessed the effectiveness of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, in elderly patients (≥65 years) with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D).
- The trial involved 82 patients who were randomly assigned to receive canagliflozin (100 mg/day) or standard therapy for 24 weeks, measuring changes in body weight (BW) and BNP concentrations as primary endpoints.
- Results showed significant weight loss in the canagliflozin group compared to standard therapy, but no significant difference in plasma BNP levels after 24 weeks, suggesting more research
Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) have beneficial cardiovascular effects, including reduction in hospitalization for heart failure (HF). The aim of this study is to explore the efficacy and safety of canagliflozin compared with standard diabetes treatment in elderly patients with type 2 diabetes (T2DM) and HF with preserved ejection fraction (HFpEF). This is a multicenter, randomized, open-label, parallel-group comparison study designed to evaluate the effects of canagliflozin on fluid retention and cardiac function in T2DM patients with HFpEF.
View Article and Find Full Text PDF